TG Therapeutics Inc. (TGTX)

6.47
0.11 1.67
NASDAQ : Health Technology
Prev Close 6.58
Open 6.56
Day Low/High 6.43 / 6.67
52 Wk Low/High 3.32 / 11.90
Volume 602.05K
Avg Volume 1.25M
Exchange NASDAQ
Shares Outstanding 94.84M
Market Cap 643.98M
EPS -2.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

TG Therapeutics Announces Data Presentations At The Upcoming 35th Annual Congress Of ECTRIMS 

TG Therapeutics Announces Data Presentations At The Upcoming 35th Annual Congress Of ECTRIMS 

Presentations include Phase 3 ULTIMATE program study design and patient demographic information, and long-term safety data from the Phase 2 trial of ublituximab in MS

TG Therapeutics Mourns The Loss Of Board Member, Mark Schoenebaum, MD

TG Therapeutics Mourns The Loss Of Board Member, Mark Schoenebaum, MD

NEW YORK, Aug. 26, 2019 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc.

Oversold Conditions For TG Therapeutics (TGTX)

Oversold Conditions For TG Therapeutics (TGTX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

TG Therapeutics Provides Business Update And Reports Second Quarter 2019 Financial Results

TG Therapeutics Provides Business Update And Reports Second Quarter 2019 Financial Results

Conference call to be held today, Friday, August 9, 2019 at 8:30 AM ET

TG Therapeutics To Host Conference Call On Second Quarter 2019 Financial Results And Business Update

TG Therapeutics To Host Conference Call On Second Quarter 2019 Financial Results And Business Update

Conference Call to be held Friday, August 9, 2019 at 8:30 AM ET

First Week Of July 19th Options Trading For TG Therapeutics (TGTX)

First Week Of July 19th Options Trading For TG Therapeutics (TGTX)

Investors in TG Therapeutics Inc saw new options begin trading this week, for the July 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the TGTX options chain for the new July 19th contracts and identified the following call contract of particular interest.

First Week Of TGTX February 2020 Options Trading

First Week Of TGTX February 2020 Options Trading

Investors in TG Therapeutics Inc saw new options begin trading this week, for the February 2020 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

TG Therapeutics (TGTX) Shares Cross Above 200 DMA

TG Therapeutics (TGTX) Shares Cross Above 200 DMA

In trading on Tuesday, shares of TG Therapeutics Inc crossed above their 200 day moving average of $6.60, changing hands as high as $6.65 per share. TG Therapeutics Inc shares are currently trading up about 1.2% on the day.

TG Therapeutics May Have Potential but the Charts Need More Work

TG Therapeutics May Have Potential but the Charts Need More Work

Shares of this biotech company are up 75% for 2019, despite recent weakness.

Baking It In: Cramer's 'Mad Money' Recap (Thursday 5/23/19)

Baking It In: Cramer's 'Mad Money' Recap (Thursday 5/23/19)

Jim Cramer says we need to bake in as much bad news as possible before the market really finds a bottom. There will be more declines ahead.

TGTX Makes Notable Cross Below Critical Moving Average

TGTX Makes Notable Cross Below Critical Moving Average

In trading on Monday, shares of TG Therapeutics Inc crossed below their 200 day moving average of $6.96, changing hands as low as $6.76 per share. TG Therapeutics Inc shares are currently trading down about 10.1% on the day.

Bullish Jobs Data: Cramer's 'Mad Money' Recap (Friday 4/5/19)

Bullish Jobs Data: Cramer's 'Mad Money' Recap (Friday 4/5/19)

It's the right amount of growth and wage gains, says Jim Cramer. And here's your game plan for next week.

Roku, FireEye, Bloom Energy: 'Mad Money' Lightning Round

Roku, FireEye, Bloom Energy: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at Roku, FireEye, Bloom Energy, Diplomat Pharmacy, People's Bank, TG Therapeutics, Tenneco, World Wrestling Entertainment, Optinose and more.

3 Promising Small Biotech Stocks to Watch

3 Promising Small Biotech Stocks to Watch

I think there is still upside left in a variety of smaller names especially if M&A activity picks up across the industry.

Keep Your Eye on the Oncology Sector Among Biotech Stocks

Keep Your Eye on the Oncology Sector Among Biotech Stocks

The myriad names in oncology have been the hottest area for acquisitions along with gene therapy.

Bullish Two Hundred Day Moving Average Cross - TGTX

Bullish Two Hundred Day Moving Average Cross - TGTX

In trading on Friday, shares of TG Therapeutics Inc crossed above their 200 day moving average of $7.72, changing hands as high as $8.31 per share. TG Therapeutics Inc shares are currently trading up about 11.4% on the day.

First Week Of November 15th Options Trading For TG Therapeutics (TGTX)

First Week Of November 15th Options Trading For TG Therapeutics (TGTX)

Investors in TG Therapeutics Inc saw new options begin trading this week, for the November 15th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Celebrating the Greatness of Individual Traders

Celebrating the Greatness of Individual Traders

Good individual traders will produce returns far in excess of anything that traditional Wall Street will earn.

Noteworthy Friday Option Activity: TGTX, SHAK, NPTN

Noteworthy Friday Option Activity: TGTX, SHAK, NPTN

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in TG Therapeutics Inc , where a total of 14,760 contracts have traded so far, representing approximately 1.5 million underlying shares. That amounts to about 74.9% of TGTX's average daily trading volume over the past month of 2.0 million shares.

3 Recent Big Gainers Kick Off the Dramatic Return of 'Small-Cap Friday'

3 Recent Big Gainers Kick Off the Dramatic Return of 'Small-Cap Friday'

Small-caps have done better than their bigger brethren so far in 2019, and these three stocks are a reason why.

MONDAY DEADLINE REMINDER: The Schall Law Firm Announces It Is Investigating Claims Against TG Therapeutics, Inc. And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

MONDAY DEADLINE REMINDER: The Schall Law Firm Announces It Is Investigating Claims Against TG Therapeutics, Inc. And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of TG Therapeutics, Inc.

MONDAY DEADLINE: The Schall Law Firm Announces It Is Investigating Claims Against TG Therapeutics, Inc. And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

MONDAY DEADLINE: The Schall Law Firm Announces It Is Investigating Claims Against TG Therapeutics, Inc. And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of TG Therapeutics, Inc.

Scott Scott Attorneys At Law LLP Reminds Investors Of Securities Class Action Against TG Therapeutics, Inc. (TGTX) And December 3 Lead Plaintiff Deadline

Scott Scott Attorneys At Law LLP Reminds Investors Of Securities Class Action Against TG Therapeutics, Inc. (TGTX) And December 3 Lead Plaintiff Deadline

Scott+Scott Attorneys at Law LLP ("Scott+Scott"), a national shareholder and consumer rights litigation firm, reminds investors that a class action lawsuit has been filed against TG Therapeutics, Inc.

Glancy Prongay & Murray LLP Reminds Investors Of The Deadline In The Class Action Lawsuit Against TG Therapeutics, Inc. Investors (TGTX)

Glancy Prongay & Murray LLP Reminds Investors Of The Deadline In The Class Action Lawsuit Against TG Therapeutics, Inc. Investors (TGTX)

Glancy Prongay & Murray LLP ("GPM") reminds investors of the December 3, 2018 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased TG Therapeutics, Inc.

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In TG Therapeutics, Inc. To Contact The Firm

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In TG Therapeutics, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in TG Therapeutics, Inc.

Federman & Sherwood Reminds Investors Of Imminent Lead Plaintiff Deadline In Securities Class Action Lawsuit Against TG Therapeutics, Inc.

Federman & Sherwood Reminds Investors Of Imminent Lead Plaintiff Deadline In Securities Class Action Lawsuit Against TG Therapeutics, Inc.

On October 4, 2018, a class action lawsuit was filed in the United States District Court for the Southern District of New York against TG Therapeutics, Inc.

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In TG Therapeutics, Inc. To Contact The Firm

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In TG Therapeutics, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in TG Therapeutics, Inc.

TheStreet Quant Rating: D- (Sell)